A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...